Abstract
Patients with Parkinson’s disease (PD) are looking forward to new therapeutic strategies that may gradually decelerate the rate of neurodegenerative decline, associated with mobility restrictions and related morbidity. Its continuous neurodegenerative process, exacerbated by genetic mutations or environmental toxins, involves a progressive reduction in the dopamine neurotransmission levels, synaptic uptake density, oxidative glucose intake, deficient striatal lactate accumulation and chronic inflammation. Over the last decade, novel bioproducts have received considerable interest due to their unique potential of unifying nutritional, safety and therapeutic natural effects. Some nutraceuticals play a crucial role in the control of the signaling transduction pathways in neurotransmission and inflammation affected in PD, and some natural compounds can beneficially interact with each one of these biological mechanisms to slow down disease progression. Atremorine, a novel plant-derived nutraceutical, probably with a neuroprotective effect in the dopaminergic neurons of the substantia nigra (pars compacta), is a prototype of this new category of bioproducts with potential effects in PD. The major focus of this review will be on the current knowledge and biomedical investigation strategies through a plant-derived neuroprotective approach to improve life quality in PD patients, being of paramount importance for health providers, caregivers and the patients themselves.
Keywords: Parkinson's disease, dopamine agonist, PD animal models, neuropathology, biotherapy, atremorine.
Current Medicinal Chemistry
Title:Dopaminergic Neuroprotection with Atremorine in Parkinson´s Disease
Volume: 25 Issue: 39
Author(s): Ivan Carrera*, Lucia Fernandez-Novoa, Carolina Sampedro, Vadim V. Tarasov, Gjumrakch Aliev and Ramon Cacabelos
Affiliation:
- Health Biotechnology, EuroEspes Biotechnology, Corunna,Spain
Keywords: Parkinson's disease, dopamine agonist, PD animal models, neuropathology, biotherapy, atremorine.
Abstract: Patients with Parkinson’s disease (PD) are looking forward to new therapeutic strategies that may gradually decelerate the rate of neurodegenerative decline, associated with mobility restrictions and related morbidity. Its continuous neurodegenerative process, exacerbated by genetic mutations or environmental toxins, involves a progressive reduction in the dopamine neurotransmission levels, synaptic uptake density, oxidative glucose intake, deficient striatal lactate accumulation and chronic inflammation. Over the last decade, novel bioproducts have received considerable interest due to their unique potential of unifying nutritional, safety and therapeutic natural effects. Some nutraceuticals play a crucial role in the control of the signaling transduction pathways in neurotransmission and inflammation affected in PD, and some natural compounds can beneficially interact with each one of these biological mechanisms to slow down disease progression. Atremorine, a novel plant-derived nutraceutical, probably with a neuroprotective effect in the dopaminergic neurons of the substantia nigra (pars compacta), is a prototype of this new category of bioproducts with potential effects in PD. The major focus of this review will be on the current knowledge and biomedical investigation strategies through a plant-derived neuroprotective approach to improve life quality in PD patients, being of paramount importance for health providers, caregivers and the patients themselves.
Export Options
About this article
Cite this article as:
Carrera Ivan *, Fernandez-Novoa Lucia , Sampedro Carolina , Tarasov V. Vadim , Aliev Gjumrakch and Cacabelos Ramon , Dopaminergic Neuroprotection with Atremorine in Parkinson´s Disease, Current Medicinal Chemistry 2018; 25 (39) . https://dx.doi.org/10.2174/0929867325666180410100559
DOI https://dx.doi.org/10.2174/0929867325666180410100559 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cell Hierarchy, Metabolic Flexibility and Systems Approaches to Cancer Treatment
Current Pharmaceutical Biotechnology Tryptophan Catabolites and Migraine
Current Pharmaceutical Design Genetic Risk Factors for Glaucoma and Exfoliation Syndrome Identified by Genome-wide Association Studies
Current Neuropharmacology Actions of Rho-Kinase Inhibitors in Cardiovascular Diseases
Current Enzyme Inhibition Signal Transduction Therapy with Rationally Designed Kinase Inhibitors
Current Signal Transduction Therapy Editorial (Thematic Issue: Myokines and Exercise Training: More Shadows than Lights)
Current Pharmaceutical Design Nongenomic Thyroxine Regulation of Voltage-gated Sodium Current During Embryonic Development
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Adult Neurogenesis and Drug Therapy
Central Nervous System Agents in Medicinal Chemistry Epigenetics in Cystic Fibrosis: Epigenetic Targeting of a Genetic Disease
Current Drug Targets The Opioid Receptor Independent Actions of Kappa Receptor Agonists in the Cardiovascular System
Current Pharmaceutical Design Analgesics in Pregnancy: An Update on Use, Safety and Pharmacokinetic Changes in Drug Disposition
Current Pharmaceutical Design Oral Administration of Thioflavin T Prevents Beta Amyloid Plaque Formation in Double Transgenic AD Mice
Current Alzheimer Research Natural Marine Anti-inflammatory Products
Mini-Reviews in Medicinal Chemistry Treating Depression in Coronary Artery Disease and Chronic Heart Failure: What’s new in using Selective Serotonin Re-Uptake Inhibitors?
Cardiovascular & Hematological Agents in Medicinal Chemistry Angiomodulatory and Neurological Effects of Ginsenosides
Current Medicinal Chemistry Preparation, Pharmacokinetic and Application of Gold Nanoclusters (AuNCs) in Tumor Treatment
Current Medicinal Chemistry Sphingolipids as Emerging Drug Targets: Therapeutic Applications of Ceramide Analogs
Drug Design Reviews - Online (Discontinued) Cerebrovascular Damage as a Cause for Alzheimers Disease
Current Neurovascular Research Muscarinic Cholinergic Contribution to Memory Consolidation: With Attention to Involvement of the Basolateral Amygdala
Current Medicinal Chemistry The Critical Period for Neuroprotection by Estrogen Replacement Therapy and the Potential Underlying Mechanisms
Current Neuropharmacology